Material Agreement Form 8 K

Item 1.01 Entry into a Material Definitive Agreement.

Amendments to 2022 Notes and 2024 Notes

Effective October 29, 2024, Arch Therapeutics, Inc. (the "Company") entered into an amendment ("Amendment No. 20 to the First 2022 Notes") with the holders of the Company's outstanding Senior Secured Convertible Promissory Notes, as separately amended on February 14, 2023, March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024, April 30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the "First 2022 Notes"), issued in connection with a private placement financing the Company completed on July 6, 2022.

Effective October 29, 2024, the Company also entered into an amendment ("Amendment No. 20 to the Second 2022 Notes") with the holders of the Company's outstanding Unsecured Convertible Promissory Notes, as separately amended on February 14, 2023, March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024, April 30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the "Second 2022 Notes"), issued in connection with a private placement financing the Company completed on January 18, 2023.

Effective October 29, 2024, the Company also entered into an amendment ("Amendment No. 15 to the Third 2022 Notes") with the holders of the Company's outstanding Unsecured Convertible Promissory Notes, as separately amended on June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024, April 30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the "Third 2022 Notes"), issued in connection with a private placement financing the Company completed on May 15, 2023.

Effective October 29, 2024, the Company also entered into an amendment ("Amendment No. 6 to the Fourth 2022 Notes") with the holders of the Company's outstanding Unsecured Convertible Promissory Notes, as separately amended on March 15, 2024, April 30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 issued in connection with a private placement financing the Company completed on March 12, 2024 (as amended, the "Fourth 2022 Notes").